MA31796B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA31796B1
MA31796B1 MA32802A MA32802A MA31796B1 MA 31796 B1 MA31796 B1 MA 31796B1 MA 32802 A MA32802 A MA 32802A MA 32802 A MA32802 A MA 32802A MA 31796 B1 MA31796 B1 MA 31796B1
Authority
MA
Morocco
Prior art keywords
antagonist
inhibitor
component
adrenoreceptor
beta
Prior art date
Application number
MA32802A
Other languages
Arabic (ar)
English (en)
Inventor
Robin Alec Fairhurst
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31796B1 publication Critical patent/MA31796B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un médicament comprenant, séparément ou ensemble :, un composant (a) qui est un agoniste de récepteur d'adénosine a2a tel que défini dans la description; et un composant (b) qui est constitué d'un ou plusieurs composés choisis parmi : (i) un corticostéroïde, (ii) un agoniste d'adrénorécepteur bêta-2, (iii) un agent antimuscarinique, (iv) un antagoniste de a 2b, (v) un antihistaminique, (vi) un inhibiteur de caspase, (vii) un inhibiteur de enac, (viii) un antagoniste de ltb4, (ix) un antagoniste de ltd4, (x) un inhibiteur de sérine protéase, (xi) un inhibiteur de pde4 et (xii) un composé à double action agoniste d'adrénorécepteur bêta-2/antagoniste muscarinique, pour une administration simultanée, séquentielle ou séparée dans le traitement d'une maladie inflammatoire ou d'obstruction des voies aériennes.
MA32802A 2007-10-17 2010-04-30 Composes organiques MA31796B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07118721 2007-10-17
PCT/EP2008/063869 WO2009050198A2 (fr) 2007-10-17 2008-10-15 Composés organiques

Publications (1)

Publication Number Publication Date
MA31796B1 true MA31796B1 (fr) 2010-10-01

Family

ID=39185790

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32802A MA31796B1 (fr) 2007-10-17 2010-04-30 Composes organiques

Country Status (21)

Country Link
US (1) US20090181934A1 (fr)
EP (1) EP2211865A2 (fr)
JP (1) JP2011500630A (fr)
KR (1) KR20100075925A (fr)
CN (1) CN101827596A (fr)
AR (1) AR068879A1 (fr)
AU (1) AU2008313788A1 (fr)
BR (1) BRPI0818005A2 (fr)
CA (1) CA2702942A1 (fr)
CL (1) CL2008003057A1 (fr)
CR (1) CR11341A (fr)
CU (1) CU20100065A7 (fr)
EA (1) EA201000617A1 (fr)
IL (1) IL204723A0 (fr)
MA (1) MA31796B1 (fr)
MX (1) MX2010004252A (fr)
PE (1) PE20091392A1 (fr)
TN (1) TN2010000168A1 (fr)
TW (1) TW200927129A (fr)
WO (1) WO2009050198A2 (fr)
ZA (1) ZA201002336B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2322525E (pt) * 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
EP1889846A1 (fr) 2006-07-13 2008-02-20 Novartis AG Dérivés de purine comme agonistes du recepteur A2a
EP1903044A1 (fr) * 2006-09-14 2008-03-26 Novartis AG Derivés de l'adénosine en tant qu' agonistes du récepteur A2A
CN101553459A (zh) * 2006-11-10 2009-10-07 诺瓦提斯公司 环戊烯二醇单乙酸酯衍生物
BRPI0818578A2 (pt) * 2007-10-17 2015-07-21 Novartis Ag Derivados de purina como ligantes receptores de adenosina a1
KR20140146217A (ko) 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
WO2026006723A1 (fr) * 2024-06-27 2026-01-02 Anand Rene Réactifs et méthodes pour traiter les céphalées, dont les migraines, ainsi que leurs comorbidités
WO2026064126A1 (fr) 2024-09-19 2026-03-26 University Of Rochester Utilisation d'inhibiteurs de gadd34 tels que sephin1 pour le traitement d'une maladie fibrotique des voies respiratoires

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2322525E (pt) * 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a

Also Published As

Publication number Publication date
AU2008313788A1 (en) 2009-04-23
JP2011500630A (ja) 2011-01-06
WO2009050198A2 (fr) 2009-04-23
IL204723A0 (en) 2010-11-30
KR20100075925A (ko) 2010-07-05
CL2008003057A1 (es) 2009-06-26
TW200927129A (en) 2009-07-01
AR068879A1 (es) 2009-12-09
ZA201002336B (en) 2011-04-28
BRPI0818005A2 (pt) 2015-04-14
EP2211865A2 (fr) 2010-08-04
US20090181934A1 (en) 2009-07-16
TN2010000168A1 (en) 2011-11-11
PE20091392A1 (es) 2009-10-14
EA201000617A1 (ru) 2010-10-29
CU20100065A7 (es) 2011-10-05
MX2010004252A (es) 2010-04-30
WO2009050198A3 (fr) 2009-09-11
CR11341A (es) 2010-05-06
CN101827596A (zh) 2010-09-08
CA2702942A1 (fr) 2009-04-23

Similar Documents

Publication Publication Date Title
MA31796B1 (fr) Composes organiques
MA29326B1 (fr) Combinaison de composes organiques
Langley et al. Nimodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease
Schmieder et al. Renin-angiotensin system and cardiovascular risk
Gradman et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension
TNSN05051A1 (fr) Therapie combinee de maladies hyperproliferatives
Vejakama et al. Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA32049B1 (fr) Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp
EP1965816A4 (fr) Compositions pharmaceutiques et procedes de traitement ou de prevention d'une maladie associee a l'oxalate
MA29606B1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
MA30607B1 (fr) N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d'antagonistes du recepteur p2x7 et procedes d'utilisation
MA29915B1 (fr) Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases
MA27999A1 (fr) Inhibiteurs de caspases contenant un cycle isoxazolinique
MA30900B1 (fr) Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
Li et al. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
Hošková et al. Tacrolimus-induced hypertension and nephrotoxicity in Fawn-Hooded rats are attenuated by dual inhibition of renin–angiotensin system
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
MA29723B1 (fr) Composes
EP1488807A4 (fr) Medicaments permettant de traiter une maladie dependant d'une hormone sexuelle